

Issue 11, October 2019

In This Issue:

- Influenza Program Information
- Adverse Reactions Following Immunization (AEFI)
- Egg Allergies/Oculo-Respiratory Syndrome (ORS)
- Reporting of Vaccines Administered
- Education
- Resources
- Additional Resources

Contacts:

Patricia Strim, Regional Nursing Lead, Immunization 250-649-7139 Patricia.Strim@northernhealth.ca



Patricia Strim, Regional Nursing Lead, Immunization

2019-2020 Influenza Program Information

For the 2019/20 publicly funded influenza campaign, influenza vaccine will be available beginning October 21, 2019.

Vaccine Ordering and Distribution

Northern Health (NH) will receive five shipments of Influenza vaccine from the end of September to the beginning of November. Distribution to CVPs will begin on October 21, 2019.

Please note that due to the incremental arrival of vaccines, NH may not be able to fill all orders completely at the onset. NH will endeavor to ensure fair and equitable distribution to all community partners and fill the orders in as few installments as possible.

As was done last season, physicians and all CVPs (pharmacists, nurses in First Nation communities, acute care, residential care facilities, workplace health & safety, and others) are required to fill out the Influenza Vaccine Order Form when ordering influenza vaccine. Pneumococcal vaccine orders can be placed at the same time.

Click here to access Influenza Vaccine Order Forms

The form can be found at: https://www.northernhealth.ca/sites/northern_health/files/health-professionals/immunization-resources/documents/vaccine-order-form-2019-20.pdf

Please fax the order to the local Health Unit at the number identified on the order form.

Influenza vaccines will be available for pick up starting the week of October 21, 2019, (date of vaccine pick up is dependent on vaccine delivery to health units).

Reminders:

- Call the Biological Product Monitor (BPM) at your local Health Unit to arrange a vaccine order pick up date. Agriflu® requires more storage space as it is packaged as a single dose pre-filled syringe. Please bring an appropriate sized cooler with cooled gel blankets and ice for vaccine pick up.
- Keep your biological fridge between 2-8° degrees celsius.
- Notify the local BPM of any



Local biological product monitor contact:



cold chain break incidents and report accordingly.

- Return unused and partially used vials of publicly funded vaccines to your BPM. Never dispose.
- Influenza vaccine can continue to be offered until the Health Unit sends out a request for annual influenza vaccine return.

About Influenza Vaccines:

Three publicly-funded vaccine products will be distributed in Northern Health this influenza season. These products reflect the following World Health Organization recommended composition of influenza virus vaccines for use in the northern hemisphere during the 2019-2020 influenza season.

Trivalent and Quadrivalent Inactivated Influenza Vaccines (TIIV & QIIV) Contains:

- A/Brisbane/02/2018 (H1N1)pdm09-like virus;
- A/Kansas/14/2017 (H3N2)like virus;
- B/Colorado/06/2017-like virus:
- B/Phuket/3073/2013like virus (in quadrivalent vaccines only)

The A/Brisbane and A/Kansas strains were not contained in the 2018/19 season vaccine.

Influenza vaccine products:

- Flulaval[®] Tetra
- Fluviral®
 NOTE: Fluviral®
 & Flulaval® Tetra
 Administration Discard multi-dose vials 28 days after first entry.
- Agriflu®

NOTE: FLUMIST® QUADRIVALENT is not available in Canada for the 2019/20 influenza season.

Intended Use of Influenza Vaccines

http://www.bccdc.ca/ resource-gallery/Documents/ Guidelines%20and%20Forms/ Guidelines%20and%20 Manuals/Epid/CD%20Manual/ Chapter%202%20-%20Imms/ Part4/Influenza_IntendedUse. pdf

For more information visit:

BCCDC Influenza (Flu) Information:

http://www.bccdc.ca/healthinfo/diseases-conditions/ influenza

BCCDC Immunization
Manual: Part 4 – Biological
Products at

http://www.bccdc.ca/healthprofessionals/clinicalresources/communicabledisease-control-manual/ immunization/biologicalproducts

Adverse Reactions Following Immunization (AEFI):

All adverse reactions following immunization with any vaccine product are to be reported to the local health unit. The Medical Health Officer's recommendations for future immunizations will be sent to the immunizer.

The form for reporting Adverse Events following Immunization is available at:

http://www.bccdc.ca/healthprofessionals/professionalresources/surveillance-forms

For more information on Adverse Events Following Immunization please visit BCCDC website at: http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/Part_5_AEFI.pdf



Egg Allergies/ Oculo-Respiratory Syndrome (ORS)

BCCDC Safety Issues Applicable to Influenza

Egg Allergic Individuals

Since the 2013/14 influenza season, British Columbia guidelines have allowed for the immunization of egg allergic individuals (including those who have experienced anaphylaxis following egg ingestion) with inactivated influenza vaccine, in any setting, following standard vaccine administration practices. These changes were based on recommendations issued by the US Joint Task Force on Practice Parameters (2013) and were reflected in the SPECIAL CONSIDERATIONS section of each of the inactivated influenza vaccine product pages for the 2013/14 season. As of the 2014/15 statement, NACI indicated that egg allergic individuals, including those who have experienced anaphylaxis following egg ingestion, can be immunized with a full dose of inactivated influenza vaccine (trivalent and quadrivalent) according to standard practices. This recommendation is supported by accumulating data on the safe immunization of these individuals using inactivated

influenza vaccines. (BCCDC Immunization Manual, 2019) For unresolved questions about egg allergies and severe Oculo-Respiratory Syndrome (ORS) you may contact your local health unit or MHO. Please see BCCDC Safety Issues Applicable to Influenza Vaccines for more details on egg allergies and ORS in the BC Communicable Disease Control (BCCDC) Manual, Chapter 2: Immunization, Part 4 – Biological Products which can be accessed at: http://www.bccdc.ca/healthprofessionals/clinicalresources/communicabledisease-control-manual/ immunization/biologicalproducts

Reporting of Vaccines



Administered

Community vaccine providers (CVPs) are asked to report required details for all clients who receive the Pneumococcal vaccine and for children 8 years of age and younger who receive Influenza vaccine, so that public health records are complete and administration of unnecessary doses is avoided. You will be provided with this form at the time you receive your vaccine.

Click here to access Influenza and Pneumococcal Reporting Forms: https://www.northernhealth.ca/sites/northern_health/files/health-professionals/immunization-resources/documents/vaccine-6-months-8-years-pneumococcal-vaccine-all-ages-2019-20.pdf

Reporting

All (CVPs) must complete the Influenza Vaccine Utilization Report. This form is used to track the number of doses administered per vaccine and the age groups that received this vaccine. This form is to be completed and returned/faxed by CVPs to the appropriate community specific health unit by January 31, 2020.

The Influenza Vaccine
Utilization Report form can
be found at: https://www.
northernhealth.ca/for-healthprofessionals/immunizationresources-tools#influenzaimmunizations

Education

For care providers new to Influenza immunizations as well as those who want in-depth information on the disease and/ or vaccines please see BCCDC Immunization Competency Course: Foundations of Influenza:Disease and Vaccines at: http://www.bccdc.ca/health-professionals/education-development/immunization-courses

For care providers who have taken the Foundations Course and/or experienced clinicians wanting an update for this Influenza season please see BCCDC Immunization Competency Course: Seasonal Influenza Update at: http://www.bccdc.ca/health-professionals/education-development/immunization-courses

Resources

- BC Communicable Disease Control (BCCDC) Manual: http://www.bccdc.ca/ dis-cond/comm-manual/ CDManualChap2.htm
- 2. Recommended composition of Influenza Virus Vaccines for use in the 2019-2020 northern hemisphere influenza season:
 WHO | Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season
- 3. FluWatch: http://
 healthycanadians.gc.ca/
 diseases-conditionsmaladies-affections/
 disease-maladie/flu-grippe/
 surveillance/index-eng.php

- 4. BCCDC Immunization Clinical Resources (See Recent updates & Q&As, Seasonal Influenza)
 - 2019/20 Seasonal Influenza Vaccine Eligibility
 - NACI statement on seasonal influenza
 - Fluzone®High-Dose Influenza Vaccine Q&A
 - BCMJ Article: Influenza vaccine in pregnancy: Is it safe?

Additional Resources

Northern Health influenza information is available at: https://www.northernhealth.ca/for-health-professionals/immunization-resources-tools?keys=immunization#influenza-immunizations#biologicals-amp-

immunizations#immunization-resources#current-issue

https://www.northernhealth. ca/health-topics/ flu?keys=flu#people-athigh-risk#people-capableof-transmitting-influenza-tothose-at-high-risk

The National Advisory Committee on Immunization (NACI):

Canadian Immunization
Guide Chapter on Influenza
and Statement on Seasonal
Influenza Vaccine for 2019–
2020 - Canada.ca

HealthlinkBC – Health files at: HealthLinkBC Files -HealthLinkBC or

- Facts about Influenza (The Flu) (12b)
- Inactivated Influenza Vaccine (12d)
- Influenza (Flu)
 Immunization: Myths and Facts (12c)
- Pneumococcal Polysaccharide Vaccine (62b)
- Why Seniors Should Get the Inactivated Influenza (Flu) Vaccine (12a)
- Influenza (Flu) Season

Immunize BC website at: https://immunizebc.ca/

BCCDC Immunization Manual: Part 4-Biological Products at: http://www.bccdc.ca/resource-gallery/Documents/Guidelines and Forms/Guidelines and Manuals/Epid/CD Manual/Chapter 2 - Imms/SectionVII_BiologicalProducts.pdf

For Health Professionals at: http://www.bccdc.ca/health-professionals











#healthynorth

northernhealth.ca 10-414-6063 (IND Rev. 10/19)